Carillon Tower Advisers’s Genomic Health, Inc. GHDX Stock Holding History

Carillon Tower Advisers’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-356,393	Closed	-$24.2M	–	497
2019 Q3	$24.2M	Buy	356,393 +291,047	+445%	+$20M	0.17%	218
2019 Q2	$3.8M	Buy	65,346 +1,300	+2%	+$77K	0.03%	410
2019 Q1	$4.49M	Sell	64,046 -100	-0.2%	-$7.42K	0.03%	391
2018 Q4	$4.13M	Sell	64,146 -11,700	-15%	-$820K	0.04%	375
2018 Q3	$5.33M	Buy	75,846 +1,493	+2%	+$87.3K	0.04%	374
2018 Q2	$3.75M	Sell	74,353 -1,022	-1%	-$40.6K	0.03%	403
2018 Q1	$2.36M	Buy	+75,375	New	+$2.5M	0.02%	427

Carillon Tower Advisers's GHDX Position: Q4 2019 in Review

Carillon Tower Advisers sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 356,393 shares — an estimated $24.2M sold.

Carillon Tower Advisers first reported a position in GHDX in Q1 2018 and held it in 7 quarters. The position peaked at $24.2M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.

Carillon Tower Advisers reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
Carillon Tower Advisers sold 356,393 Genomic Health, Inc. shares in Q4 2019, an estimated $24.2M.
Carillon Tower Advisers first reported a position in Genomic Health, Inc. in Q1 2018 and held it in 7 quarters.
Carillon Tower Advisers's Genomic Health, Inc. position peaked at $24.2M in Q3 2019.
0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.

Based on Carillon Tower Advisers's 13F filing for Q4 2019, filed 11 Feb 2020.